Venture financing deals in pharma rise in H2 2021
The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.
Still, this growth is less impressive compared to the 81.1% rise in pharma VC deals seen in H1 compared to the same period in 2020
In the second half of 2021 venture financing deals increased by 12.4% from the same period in 2020.
This marks a deceleration in growth from the 81.1% increase in deals seen from the first six months of 2020 to the same period in 2021.
During this time, the region that saw the biggest increase in the number of deals was Europe.
Deals rose by 375% in the region.
From the second half of 2020 to the second half of 2021, the largest regional increase in deals was seen in The Asia-Pacific region.
The region saw a 100% increase in deals.
During second half of 2021, venture financing deals accounted for 13.9% of deals taking place in the sector. This represents an increase from the figure of 5.1% in second half of 2020.
GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.
The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.
By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.
The highest value venture financing deal that took place in 2021 (where the deal value was known) was the $225 million secured by Exscientia Raises.
The database states that the rationale behind this deal was as follows: "The company intends to use the proceeds to advance its proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design."